Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling
Chuan Xu, … , Xiu-Wu Bian, Hui-Kuan Lin
Chuan Xu, … , Xiu-Wu Bian, Hui-Kuan Lin
Published March 1, 2022
Citation Information: J Clin Invest. 2022;132(5):e141797. https://doi.org/10.1172/JCI141797.
View: Text | PDF
Research Article Immunology

SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling

  • Text
  • PDF
Abstract

Cancer stem-like cells (CSLCs) acquire enhanced immune checkpoint responses to evade immune cell killing and promote tumor progression. Here we showed that signal regulatory protein γ (SIRPγ) determined CSLC properties and immune evasiveness in a small population of lung adenocarcinoma (LUAD) cancer cells. A SIRPγhi population displayed CSLC properties and transmitted the immune escape signal through sustaining CD47 expression in both SIRPγhi and SIRPγlo/– tumor cells. SIRPγ bridged MST1 and PP2A to facilitate MST1 dephosphorylation, resulting in Hippo/YAP activation and leading to cytokine release by CSLCs, which stimulated CD47 expression in LUAD cells and consequently inhibited tumor cell phagocytosis. SIRPγ promoted tumor growth and metastasis in vivo through YAP signaling. Notably, SIRPγ targeting with genetic SIRPγ knockdown or a SIRPγ-neutralizing antibody inhibited CSLC phenotypes and elicited phagocytosis that suppressed tumor growth in vivo. SIRPG was upregulated in human LUAD and its overexpression predicted poor survival outcome. Thus, SIRPγhi cells serve as CSLCs and tumor immune checkpoint–initiating cells, propagating the immune escape signal to the entire cancer cell population. Our study identifies Hippo/YAP signaling as the first mechanism by which SIRPγ is engaged and reveals that targeting SIRPγ represents an immune- and CSLC-targeting strategy for lung cancer therapy.

Authors

Chuan Xu, Guoxiang Jin, Hong Wu, Wei Cui, Yu-Hui Wang, Rajesh Kumar Manne, Guihua Wang, Weina Zhang, Xian Zhang, Fei Han, Zhen Cai, Bo-Syong Pan, Che-Chia Hsu, Yiqiang Liu, Anmei Zhang, Jie Long, Hongbo Zou, Shuang Wang, Xiaodan Ma, Jinling Duan, Bin Wang, Weihui Liu, Haitao Lan, Qing Xiong, Gang Xue, Zhongzhu Chen, Zhigang Xu, Mark E. Furth, Sarah Haigh Molina, Yong Lu, Dan Xie, Xiu-Wu Bian, Hui-Kuan Lin

×

Figure 3

SIRPγ serves as a negative upstream regulator of the MST1/LATS1 axis to promote YAP activation and cancer organoid growth.

Options: View larger image (or click on image) Download as PowerPoint
SIRPγ serves as a negative upstream regulator of the MST1/LATS1 axis to ...
(A and B) Immunoblotting analysis of indicated proteins in control and SIRPγ-knockdown A549 (A) and H1975 (B) cells. (C and D) Immunoblotting analysis of indicated proteins in control and SIRPγ-overexpressing cells. (E) Immunoblotting analysis of indicated proteins in SIRPγlo/– and SIRPγhi A549 cancer cells. (F and G) Stem cell sphere assay of YAP-overexpressing or -knockdown A549 (F) or H1975 (G) cells (1 × 103 cells/well). (H and I) Stem cell sphere formation assay and immunoblotting analysis of vector- and SIRPγ-overexpressing A549 (H) or H1975 (I) cells with or without YAP knockdown. (J) H&E staining of tumor tissue derived from patients with LUAD. Scale bars: 50 μm. (K and L) Representative images are shown for the growth of LUAD-derived organoids of indicated groups grown in matrigel-supplemented media for 7 days. Quantification of the growth of organoids. Scale bars: 20 μm. All experiments were carried out at least in triplicate and the data are presented as the mean ± SD. *P < 0.05; **P < 0.01 by paired, 2-tailed Student’s t test (F and G, left panels) or 1-way ANOVA (F, G [right panels in both], H, I, K, and L).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts